A retrospective study carried out in a tertiary care hospital in India that included patients with type 2 diabetes receiving SGLT2 inhibitors for at least 12 months (120 participants) showed that 16.6% of patients presented one or more episodes of genital mycotic infections, while 3.3% patients developed urinary tract infections. This evidence concerns the gene SLC5A2 and urinary tract infection.